Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12004379 | 0.86 | ALOX5AP (0.42) | ALOX5APCYP2C9CYP2D6 | |
| SCHEMBL15166465 | 0.79 | ALOX5AP (0.37) | ALOX5APCYP2C9CYP2D6 | |
| SCHEMBL12019813 | 0.78 | ALOX5AP (0.43) | ALOX5APCYP2C9CYP2D6 | |
| SCHEMBL10161777 | 0.78 | ALOX5AP (0.43) | ALOX5APCYP2C9CYP2D6 | |
| SCHEMBL669323 | 0.76 | ALOX5AP (0.45) | ALOX5AP | |
| SCHEMBL15167101 | 0.76 | CYP19A1 (0.40) | — | |
| SCHEMBL15166464 | 0.75 | ALOX5AP (0.47) | ALOX5APCYP2C9CYP2D6 | |
| SCHEMBL10161422 | 0.75 | ALOX5AP (0.47) | ALOX5APCYP2C9CYP2D6 | |
| SCHEMBL10161761 | 0.73 | ALOX5AP (0.44) | ALOX5APCYP2C9CYP2D6 | |
| SCHEMBL17399665 | 0.73 | ALOX5AP (0.39) | ALOX5APCYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809321-B1 | PHENYL-C-OXADIAZOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE PRODUCTION FOR USE IN COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| EP-2606045-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8658661-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | ALOX5AP 17/4885CYP2C9 272/4885CYP2D6 294/4885 |
| US-20130195879-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | ALOX5AP 24/4885CYP2C9 410/4885CYP2D6 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.